Floatz logo

Raltitrexed

Rectal Cancer

Fudan UniversitySmall moleculePhase 2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

113 Active assets in the Rectal Cancer cohort.

View all 50

Same molecule, other indications

Raltitrexed is also rated in:

Hepatic Arterial Infusion ChemotherapyDormant
BBB
Indicative ·
74 / 100
View asset →
Colon Cancer Liver MetastasisDormant
BB
Indicative ·
71 / 100
View asset →
Hepatocellular CarcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →